Cargando…
Clinically aggressive pediatric spinal ependymoma with novel MYC amplification demonstrates molecular and histopathologic similarity to newly described MYCN-amplified spinal ependymomas
Primary spinal cord tumors contribute to ≤ 10% of central nervous system tumors in individuals of pediatric or adolescent age. Among intramedullary tumors, spinal ependymomas make up ~ 30% of this rare tumor population. A twelve-year-old male presented with an intradural, extramedullary mass occupyi...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665631/ https://www.ncbi.nlm.nih.gov/pubmed/34895332 http://dx.doi.org/10.1186/s40478-021-01296-2 |
_version_ | 1784614049381613568 |
---|---|
author | Shatara, Margaret Schieffer, Kathleen M. Klawinski, Darren Thomas, Diana L. Pierson, Christopher R. Sribnick, Eric A. Jones, Jeremy Rodriguez, Diana P. Deeg, Carol Hamelberg, Elizabeth LaHaye, Stephanie Miller, Katherine E. Fitch, James Kelly, Benjamin Leraas, Kristen Pfau, Ruthann White, Peter Magrini, Vincent Wilson, Richard K. Mardis, Elaine R. Abdelbaki, Mohamed S. Finlay, Jonathan L. Boué, Daniel R. Cottrell, Catherine E. Ghasemi, David R. Pajtler, Kristian W. Osorio, Diana S. |
author_facet | Shatara, Margaret Schieffer, Kathleen M. Klawinski, Darren Thomas, Diana L. Pierson, Christopher R. Sribnick, Eric A. Jones, Jeremy Rodriguez, Diana P. Deeg, Carol Hamelberg, Elizabeth LaHaye, Stephanie Miller, Katherine E. Fitch, James Kelly, Benjamin Leraas, Kristen Pfau, Ruthann White, Peter Magrini, Vincent Wilson, Richard K. Mardis, Elaine R. Abdelbaki, Mohamed S. Finlay, Jonathan L. Boué, Daniel R. Cottrell, Catherine E. Ghasemi, David R. Pajtler, Kristian W. Osorio, Diana S. |
author_sort | Shatara, Margaret |
collection | PubMed |
description | Primary spinal cord tumors contribute to ≤ 10% of central nervous system tumors in individuals of pediatric or adolescent age. Among intramedullary tumors, spinal ependymomas make up ~ 30% of this rare tumor population. A twelve-year-old male presented with an intradural, extramedullary mass occupying the dorsal spinal canal from C6 through T2. Gross total resection and histopathology revealed a World Health Organization (WHO) grade 2 ependymoma. He recurred eleven months later with extension from C2 through T1-T2. Subtotal resection was achieved followed by focal proton beam irradiation and chemotherapy. Histopathology was consistent with WHO grade 3 ependymoma. Molecular profiling of the primary and recurrent tumors revealed a novel amplification of the MYC (8q24) gene, which was confirmed by fluorescence in situ hybridization studies. Although MYC amplification in spinal ependymoma is exceedingly rare, a newly described classification of spinal ependymoma harboring MYCN (2p24) amplification (SP-MYCN) has been defined by DNA methylation-array based profiling. These individuals typically present with a malignant progression and dismal outcomes, contrary to the universally excellent survival outcomes seen in other spinal ependymomas. DNA methylation array-based classification confidently classified this tumor as SP-MYCN ependymoma. Notably, among the cohort of 52 tumors comprising the SP-MYCN methylation class, none harbor MYC amplification, highlighting the rarity of this genomic amplification in spinal ependymoma. A literature review comparing our individual to reported SP-MYCN tumors (n = 26) revealed similarities in clinical, histopathologic, and molecular features. Thus, we provide evidence from a single case to support the inclusion of MYC amplified spinal ependymoma within the molecular subgroup of SP-MYCN. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40478-021-01296-2. |
format | Online Article Text |
id | pubmed-8665631 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-86656312021-12-13 Clinically aggressive pediatric spinal ependymoma with novel MYC amplification demonstrates molecular and histopathologic similarity to newly described MYCN-amplified spinal ependymomas Shatara, Margaret Schieffer, Kathleen M. Klawinski, Darren Thomas, Diana L. Pierson, Christopher R. Sribnick, Eric A. Jones, Jeremy Rodriguez, Diana P. Deeg, Carol Hamelberg, Elizabeth LaHaye, Stephanie Miller, Katherine E. Fitch, James Kelly, Benjamin Leraas, Kristen Pfau, Ruthann White, Peter Magrini, Vincent Wilson, Richard K. Mardis, Elaine R. Abdelbaki, Mohamed S. Finlay, Jonathan L. Boué, Daniel R. Cottrell, Catherine E. Ghasemi, David R. Pajtler, Kristian W. Osorio, Diana S. Acta Neuropathol Commun Case Report Primary spinal cord tumors contribute to ≤ 10% of central nervous system tumors in individuals of pediatric or adolescent age. Among intramedullary tumors, spinal ependymomas make up ~ 30% of this rare tumor population. A twelve-year-old male presented with an intradural, extramedullary mass occupying the dorsal spinal canal from C6 through T2. Gross total resection and histopathology revealed a World Health Organization (WHO) grade 2 ependymoma. He recurred eleven months later with extension from C2 through T1-T2. Subtotal resection was achieved followed by focal proton beam irradiation and chemotherapy. Histopathology was consistent with WHO grade 3 ependymoma. Molecular profiling of the primary and recurrent tumors revealed a novel amplification of the MYC (8q24) gene, which was confirmed by fluorescence in situ hybridization studies. Although MYC amplification in spinal ependymoma is exceedingly rare, a newly described classification of spinal ependymoma harboring MYCN (2p24) amplification (SP-MYCN) has been defined by DNA methylation-array based profiling. These individuals typically present with a malignant progression and dismal outcomes, contrary to the universally excellent survival outcomes seen in other spinal ependymomas. DNA methylation array-based classification confidently classified this tumor as SP-MYCN ependymoma. Notably, among the cohort of 52 tumors comprising the SP-MYCN methylation class, none harbor MYC amplification, highlighting the rarity of this genomic amplification in spinal ependymoma. A literature review comparing our individual to reported SP-MYCN tumors (n = 26) revealed similarities in clinical, histopathologic, and molecular features. Thus, we provide evidence from a single case to support the inclusion of MYC amplified spinal ependymoma within the molecular subgroup of SP-MYCN. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40478-021-01296-2. BioMed Central 2021-12-11 /pmc/articles/PMC8665631/ /pubmed/34895332 http://dx.doi.org/10.1186/s40478-021-01296-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Case Report Shatara, Margaret Schieffer, Kathleen M. Klawinski, Darren Thomas, Diana L. Pierson, Christopher R. Sribnick, Eric A. Jones, Jeremy Rodriguez, Diana P. Deeg, Carol Hamelberg, Elizabeth LaHaye, Stephanie Miller, Katherine E. Fitch, James Kelly, Benjamin Leraas, Kristen Pfau, Ruthann White, Peter Magrini, Vincent Wilson, Richard K. Mardis, Elaine R. Abdelbaki, Mohamed S. Finlay, Jonathan L. Boué, Daniel R. Cottrell, Catherine E. Ghasemi, David R. Pajtler, Kristian W. Osorio, Diana S. Clinically aggressive pediatric spinal ependymoma with novel MYC amplification demonstrates molecular and histopathologic similarity to newly described MYCN-amplified spinal ependymomas |
title | Clinically aggressive pediatric spinal ependymoma with novel MYC amplification demonstrates molecular and histopathologic similarity to newly described MYCN-amplified spinal ependymomas |
title_full | Clinically aggressive pediatric spinal ependymoma with novel MYC amplification demonstrates molecular and histopathologic similarity to newly described MYCN-amplified spinal ependymomas |
title_fullStr | Clinically aggressive pediatric spinal ependymoma with novel MYC amplification demonstrates molecular and histopathologic similarity to newly described MYCN-amplified spinal ependymomas |
title_full_unstemmed | Clinically aggressive pediatric spinal ependymoma with novel MYC amplification demonstrates molecular and histopathologic similarity to newly described MYCN-amplified spinal ependymomas |
title_short | Clinically aggressive pediatric spinal ependymoma with novel MYC amplification demonstrates molecular and histopathologic similarity to newly described MYCN-amplified spinal ependymomas |
title_sort | clinically aggressive pediatric spinal ependymoma with novel myc amplification demonstrates molecular and histopathologic similarity to newly described mycn-amplified spinal ependymomas |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665631/ https://www.ncbi.nlm.nih.gov/pubmed/34895332 http://dx.doi.org/10.1186/s40478-021-01296-2 |
work_keys_str_mv | AT shataramargaret clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas AT schiefferkathleenm clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas AT klawinskidarren clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas AT thomasdianal clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas AT piersonchristopherr clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas AT sribnickerica clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas AT jonesjeremy clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas AT rodriguezdianap clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas AT deegcarol clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas AT hamelbergelizabeth clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas AT lahayestephanie clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas AT millerkatherinee clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas AT fitchjames clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas AT kellybenjamin clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas AT leraaskristen clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas AT pfauruthann clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas AT whitepeter clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas AT magrinivincent clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas AT wilsonrichardk clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas AT mardiselainer clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas AT abdelbakimohameds clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas AT finlayjonathanl clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas AT bouedanielr clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas AT cottrellcatherinee clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas AT ghasemidavidr clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas AT pajtlerkristianw clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas AT osoriodianas clinicallyaggressivepediatricspinalependymomawithnovelmycamplificationdemonstratesmolecularandhistopathologicsimilaritytonewlydescribedmycnamplifiedspinalependymomas |